AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Collegium Pharmaceutical Inc (NASDAQ:COLL)
31.06 USD
+0.580 1.903%Sponsored Reports
Loading...
| Previous Close (in USD) | 30.48 |
|---|---|
| Change | +0.580 1.903% |
| 52 W H/L (in USD) | 50.787/25.980 |
| EBITDA (in USD) | 419.164M |
| PE Ratio | 19.23 |
| Volume | 474229 |
| Diluted Eps TTM | 1.73 |
| Total Assets (in USD) | 1656.834M |
|---|---|
| Total Liabilities (in USD) | 1355.159M |
| Revenue TTM (in USD) | 780.567M |
| Cash (in USD) | 251.102M |
| Market Cap (in USD) | 1,078.180 M |
| Revenue Per Share TTM | 24.619 |
| Gross Profit TTM (in USD) | 693.638M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
100 Technology Center Drive, Stoughton, MA, United States, 02072
781 713 3699
Employees: 423
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder & Chairman | 1964 |
| 2. | Mr. Joseph J. Ciaffoni | Pres, CEO & Director | 1971 |
| 3. | Ms. Colleen Tupper | Exec. VP & CFO | 1976 |
| 4. | Ms. Shirley R. Kuhlmann | Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. | 1984 |
| 5. | Mr. Scott Dreyer | Exec. VP & Chief Commercial Officer | 1973 |
| 6. | Dr. Richard Malamut M.D. | Exec. VP & Chief Medical Officer | 1960 |
| 7. | Ms. Alex Dasalla | Head of Investor Relations | NA |
| 8. | Mr. Bart J. Dunn | Exec. VP of Strategy & Corp. Devel. | NA |
| 9. | Ms. Marlo Manning | Head of HR | NA |
| 10. | Mr. Scott Sudduth | Head of Technical Operations | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
+1.200 1.571% | 76.22 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
+0.580 1.906% | 30.72 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
0.000 0.000% | 153.91 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.790 1.894% | 41.335 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 92.619M | 98.568M | 75.733M | -28.847M | -3.374M |
| Minority Interest | - | - | - | - | - |
| Net Income | 62.87M | 69.19M | 48.155M | -25.002M | 71.517M |
| Selling General Administrative | 284.803M | 172.32M | 151.802M | 172.186M | 118.96M |
| Gross Profit | 463.257M | 377.344M | 326.169M | 209.488M | 150.617M |
| Reconciled Depreciation | 226.074M | 169.16M | 149.256M | 138.939M | 68.917M |
| Ebit | 174.931M | 172.542M | 159.072M | -104.573M | -46.699M |
| Ebitda | 401.005M | 341.702M | 308.328M | 34.366M | 22.218M |
| Depreciation And Amortization | 226.074M | 169.16M | 149.256M | 138.939M | 68.917M |
| Operating Income | 187.084M | 169.895M | 166.961M | -104.573M | -46.699M |
| Other Operating Expenses | 593.483M | 461.554M | 399.806M | 430.614M | 254.662M |
| Interest Expense | 82.312M | 73.974M | 83.339M | 63.213M | 21.014M |
| Tax Provision | 29.749M | 29.378M | 27.578M | -3.845M | -74.891M |
| Interest Income | 11.289M | 13.976M | 15.615M | 1.047M | 0.012M |
| Net Interest Income | -71.023M | -59.998M | -67.724M | -62.166M | -21.002M |
| Income Tax Expense | 29.749M | 29.378M | 27.578M | -3.845M | -74.891M |
| Total Revenue | 780.567M | 631.449M | 566.767M | 463.933M | 276.868M |
| Total Operating Expenses | 276.173M | 207.449M | 159.208M | 176.169M | 128.411M |
| Cost Of Revenue | 317.31M | 254.105M | 240.598M | 254.445M | 126.251M |
| Total Other Income Expense Net | -94.465M | -71.327M | -91.228M | 75.726M | 43.325M |
| Net Income From Continuing Ops | 62.87M | 69.19M | 48.155M | -25.002M | 71.517M |
| Net Income Applicable To Common Shares | - | - | - | -25.002M | 71.517M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 1656.834M | 1663.591M | 1143.308M | 1174.131M | 692.077M |
| Intangible Assets | 669.51M | 891.402M | 421.708M | 567.468M | 268.723M |
| Other Current Assets | 32.642M | 55.394M | 0.093M | 16.681M | 0.027M |
| Total Liab | 1355.159M | 1434.749M | 947.877M | 979.289M | 489.149M |
| Total Stockholder Equity | 301.675M | 228.842M | 195.431M | 194.842M | 202.928M |
| Other Current Liab | 398.295M | 424.537M | 264.902M | 66.879M | 147.829M |
| Common Stock | 0.041M | 0.04M | 0.038M | 0.037M | 0.036M |
| Capital Stock | 0.041M | 0.04M | 0.038M | 0.037M | 0.036M |
| Retained Earnings | -101.129M | -163.999M | -233.189M | -281.344M | -256.342M |
| Good Will | 145.925M | 162.333M | 133.857M | 133.695M | - |
| Other Assets | - | - | - | 19.328M | 942.739M |
| Cash | 251.102M | 70.565M | 238.947M | 173.688M | 186.426M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 440.028M | 509.51M | 457.915M | 270.114M | 230.399M |
| Current Deferred Revenue | 0.667M | 10M | - | - | - |
| Net Debt | 689.457M | 788.733M | 435.336M | 699.099M | 72.324M |
| Short Term Debt | 30.407M | 65.854M | 184.321M | 163.612M | 49.167M |
| Short Long Term Debt | 29M | 64.583M | 183.333M | 162.5M | 48.353M |
| Short Long Term Debt Total | 940.559M | 859.298M | 674.283M | 872.787M | 258.75M |
| Other Stockholder Equity | 402.444M | 392.746M | 428.568M | 476.149M | 459.234M |
| Property Plant Equipment | - | - | - | 19.521M | 19.491M |
| Total Current Assets | 691.411M | 482.257M | 537.6M | 419.989M | 315.543M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 155.427M | 92.198M | 71.601M | - | - |
| Net Receivables | 211.328M | 228.54M | 179.525M | 183.119M | 105.844M |
| Long Term Debt | 780.325M | 787.905M | 483.838M | 538.451M | 201.632M |
| Inventory | 40.912M | 35.56M | 32.332M | 46.501M | 17.394M |
| Accounts Payable | 10.659M | 3.934M | 8.692M | 39.623M | 33.403M |
| Accumulated Other Comprehensive Income | 0.319M | 0.055M | 0.014M | - | - |
| Non Currrent Assets Other | 20.193M | 9.415M | 0.825M | 2.647M | 2.634M |
| Non Current Assets Total | 965.423M | 1181.334M | 605.708M | 754.142M | 376.534M |
| Capital Lease Obligations | 5.539M | 6.81M | 7.112M | 8.224M | 8.765M |
| Long Term Debt Total | - | - | - | 538.451M | 201.632M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -61.792M | -287.759M | -46.655M | -573.691M | -1.944M |
| Total Cashflows From Investing Activities | -63.532M | -287.759M | -70.812M | -573.691M | -1.944M |
| Total Cash From Financing Activities | -110.245M | -60.603M | -140.178M | 436.723M | -89.303M |
| Net Income | 62.87M | 69.19M | 48.155M | -25.002M | 71.517M |
| Change In Cash | 155.546M | -143.382M | 63.759M | -12.738M | 12.31M |
| Begin Period Cash Flow | 96.612M | 239.994M | 176.235M | 188.973M | 176.663M |
| End Period Cash Flow | 252.158M | 96.612M | 239.994M | 176.235M | 188.973M |
| Total Cash From Operating Activities | 329.323M | 204.98M | 274.749M | 124.23M | 103.557M |
| Depreciation | 220.82M | 169.16M | 149.256M | 138.939M | 68.917M |
| Other Cashflows From Investing Activities | - | - | - | -572.069M | - |
| Dividends Paid | - | - | 9.101M | - | - |
| Change To Inventory | -5.353M | 13.927M | 14.169M | 48.274M | -2.296M |
| Sale Purchase Of Stock | -25.104M | -60.025M | -75M | -14.063M | -47.861M |
| Other Cashflows From Financing Activities | -20.401M | -8.097M | 0.74M | 513.975M | 8.558M |
| Capital Expenditures | 1.74M | 1.652M | 0.461M | 1.622M | 1.944M |
| Change In Working Capital | 3.76M | -54.978M | 21.731M | -12.713M | 13.486M |
| Other Non Cash Items | 25.624M | 16.022M | 30.624M | 8.523M | 3.424M |
| Free Cash Flow | 327.583M | 203.328M | 274.288M | 122.608M | 101.613M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 2 months ago | 1896942 |
| 2. | FullerThaler Beh Small-Cap Equity SMA | 5 months ago | 1430708 |
| 3. | FullerThaler Behavioral Small-Cap Equity | 5 months ago | 1430708 |
| 4. | FullerThaler Behavioral Sm-Cp Eq R6 | 5 months ago | 1430708 |
| 5. | Eventide Gilead N | 5 months ago | 1344376 |
| 6. | Janus Henderson Hrzn Glb SC E2 USD | 3 months ago | 983459 |
| 7. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 948657 |
| 8. | iShares Russell 2000 ETF | 2 months ago | 760928 |
| 9. | Principal U.S. Small Cap Select Equity | 5 months ago | 548500 |
| 10. | Principal U.S. Small Cap Equity | 5 months ago | 548500 |
| 11. | MFS New Discovery I | 3 months ago | 538945 |
| 12. | Eventide Healthcare & Life Sciences I | 5 months ago | 517159 |
| 13. | Principal SmallCap R5 | 3 months ago | 495900 |
| 14. | MFS New Discovery Value I | 3 months ago | 395816 |
| 15. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 353163 |
| 16. | Avantis US Small Cap Value ETF | 2 months ago | 320918 |
| 17. | Fidelity Small Cap Index | 4 months ago | 303761 |
| 18. | Invesco Small Cap Core | 5 months ago | 293623 |
| 19. | State Street SPDR Port S&P 600 Sm CpETF | 2 months ago | 288950 |
| 20. | Invesco Main Street Small Cap R6 | 3 months ago | 287807 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 8 months ago | 5178044 |
| 2. | Fuller & Thaler Asset Management Inc | 5 months ago | 3000144 |
| 3. | Vanguard Group Inc | 5 months ago | 2256254 |
| 4. | Eventide Asset Management, LLC | 5 months ago | 1876239 |
| 5. | Renaissance Technologies Corp | 5 months ago | 1617349 |
| 6. | Rubric Capital Management LP | 5 months ago | 1496436 |
| 7. | Massachusetts Financial Services Company | 5 months ago | 1312655 |
| 8. | Principal Financial Group Inc | 8 months ago | 1309771 |
| 9. | State Street Corp | 8 months ago | 1293911 |
| 10. | Amvescap Plc. | 8 months ago | 1282971 |
| 11. | HHG PLC | 8 months ago | 910241 |
| 12. | Dimensional Fund Advisors, Inc. | 5 months ago | 830480 |
| 13. | Geode Capital Management, LLC | 5 months ago | 829453 |
| 14. | Morgan Stanley - Brokerage Accounts | 8 months ago | 767420 |
| 15. | D. E. Shaw & Co LP | 5 months ago | 653874 |
| 16. | The Goldman Sachs Group Inc | 5 months ago | 647537 |
| 17. | Emerald Advisers, LLC | 5 months ago | 629344 |
| 18. | Arrowstreet Capital Limited Partnership | 5 months ago | 543773 |
| 19. | Assenagon Asset Management SA | 5 months ago | 511698 |
| 20. | Marshall Wace Asset Management Ltd | 5 months ago | 492360 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...